Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Pathology

Physiology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(16)31419-2

License

CC-BY-NC-ND

Other Formats

PDF